Mahmoud Elsohly, PhD, is a pharmacologist known for his work on marijuana. He is professor of pharmaceutics in the school of pharmacy at the University of Mississippi where he directs the Marijuana Project which grows pharmaceutical-grade marijuana for research. He is an expert in the processing, testing, and detection of drugs of abuse.
Legalization of marijuana is becoming increasingly prominent in the United States and around the world. While there is some discussion of the relationship between marijuana and overall health, a comprehensive resource that outlines the medical literature for several organ systems, as well as non-medical societal effects, has yet to be seen. While all physicians strive to practice evidence-based medicine, many clinicians aren’t aware of the facts surrounding cannabis and are guided by public opinion.
This first of its kind book is a comprehensive compilation of multiple facets of cannabis recommendation, use and effects from a variety of different perspectives. Comprised of chapters dedicated to separate fields of medicine, this evidence-based guide outlines the current data, or lack thereof, as well as the need for further study. The book begins with a general overview of the neurobiology and pharmacology of THC and hemp. It then delves into various medical concerns that plague specific disciplines of medicine such as psychiatry, cardiology, gastrointestinal and neurology, among others. The end of the book focuses on non-medical concerns such as public health and safety, driving impairment and legal implications.
Comprised of case studies and meta-analyses, Cannabis in Medicine: An Evidence-Based Approach provides clinicians with a concise, evidence-based guide to various health concerns related to the use of marijuana. By addressing non-medical concerns, this book is also a useful resource for professionals working in the public health and legal fields.
No evidence was found of a significant relation between lifetime “ever” cannabis use and the subsequent development of testicular cancer [n = 45 250; 119 testicular cancer cases; adjusted hazard ratio (AHR) 1.42, 95% CI, 0.83, 2.45]. “Heavy” cannabis use (defined as usage of more than 50 times in lifetime, as measured at conscription) was associated with the incidence of testicular cancer (n = 45 250; 119 testicular cancer cases; AHR 2.57, 95% CI, 1.02, 6.50).
The current study provides additional evidence to the limited prior literature suggesting cannabis use may contribute to the development of testicular cancer.
Researchers at the University of California San Diego School of Medicine have identified the molecular mechanism activated by the presence of tetrahydrocannabinol (THC) in the bloodstream that accelerates cancer growth in patients with HPV-positive head and neck squamous cell carcinoma.
“HPV-related head and neck cancer is one of the fastest growing cancers in the United States, while at the same time, exposure to marijuana is accelerating. This is a huge public health problem,” said Joseph A. Califano III, MD, senior author and professor and vice chief of the Division of Otolaryngology in the school’s Department of Surgery.
Head and neck squamous cell carcinoma is the sixth most common cancer worldwide, the school reports. These cancers begin in the cells that line the mucous membranes inside the mouth, nose, and throat. About 30% of cases are related to HPV infection, and these cases in particular are on the rise